ArriVent BioPharma, Inc.

What they do

ArriVent is a clinical-stage biopharmaceutical company focused on developing and commercializing differentiated medicines for cancer, with an initial focus on solid tumors. Its lead product candidate, firmonertinib, is an EGFR mutant-selective tyrosine kinase inhibitor being developed for non-small cell lung cancer (NSCLC) across a range of EGFR mutations, including exon 20 insertions and PACC mutations. The company also has a pipeline of next-generation antibody drug conjugates (ADCs), including ARR-217 (MRG007) and ARR-002. ArriVent licensed worldwide rights to firmonertinib from Shanghai Allist Pharmaceuticals, excluding greater China, where Allist holds rights.

Revenue drivers

• Firmonertinib — Lead product candidate; not yet approved by FDA; currently in pivotal Phase 3 trials for first-line EGFR exon 20 insertion and PACC mutant NSCLC; no revenue generated from sales.
• ARR-217 (MRG007) — CDH17-targeted ADC in Phase 1 clinical trial for gastrointestinal malignancies; no revenue yet; partnered with Lepu Biopharma.
• ARR-002 — Dual-target MUC16/NaPi2b tetravalent ADC; first-in-human study planned for ovarian and endometrial cancers; exclusive greater China license granted to Allist; no revenue yet.

Recent performance

For the six months ended June 30, 2026, ArriVent reported a net loss of $93.2 million, compared to a net loss of $95.8 million for the same period in 2025. Research and development expenses were $80.0 million and general and administrative expenses were $18.8 million for the first half of 2026. Net cash used in operations was $81.5 million for the first half of 2026. As of June 30, 2026, the company had cash and investments of $373.1 million. No revenue has been generated to date.

Strategy

ArriVent is prioritizing the advancement of firmonertinib through global pivotal Phase 3 trials (FURVENT and ALPACCA) to establish it as a first-line treatment for uncommon EGFR mutations in NSCLC. The company is also building a differentiated ADC portfolio, with ARR-217 advancing into Phase 1b dose optimization and ARR-002 entering clinical development. The company entered into an exclusive licensing agreement with Allist for ARR-002 in greater China, retaining all other rights. Management expects to present pivotal topline data from the FURVENT study and initial Phase 1 data for ARR-217.

Risks

• No approved products or revenue — ArriVent has no approved products and has incurred significant operating losses since inception; profitability may never be achieved.
• Clinical trial failure — Firmonertinib and ADC candidates are in clinical development; failure of pivotal trials (FURVENT, ALPACCA) would materially harm the business.
• Dependence on third-party partners — The company relies on Allist for firmonertinib development in greater China and on Lepu Biopharma for ARR-217; partnership performance affects prospects.
• Substantial capital needs — Operating requires substantial additional capital; if not obtained on acceptable terms, the company may be forced to delay or curtail development.

Outlook

Management expects to report topline data from the global pivotal FURVENT Phase 3 study for first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026. Initial Phase 1 dose escalation data for ARR-217 are planned for presentation at a future medical conference. Dosing of the first patient with ARR-002 is expected in the third quarter of 2026. Cash and investments of $373.1 million are expected to fund operations into 2028.